Glenmark Pharma Q1 - Fabiflu Sales Taper To Weaken India Results; To Offset By Other Geographies: KRChoksey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Glenmark Pharmaceuticals Ltd. reported 26.4% YoY revenue growth (up 3.7% QoQ) to Rs 29,649 million led by growth across all its major markets such as India, U.S., Europe Union, Latin America and in active pharma ingredient segments, YoY.
Sequentially, the growth was driven by strong growth in India segment, alone, partially offset by decline in all other geographical revenue segments.
Glenmark Pharma's Ebitda grew 20.0% YoY to Rs 5,736 million while Ebitda margin contracted 104 basis points YoY to 19.3% due to reduced gross profits margin YoY and QoQ.
Net profits margin increased 70 bps YoY to 10.3% in Q1 FY22 due to reduction in interest expenses, YoY and QoQ, partially offset by flat growth in other income YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.